REPROVA

For decades, contraception has largely been framed as a women’s responsibility. Innovation seen through pills, patches, injections, and coils, has moved forward, but mostly in one direction. However, this is quietly changing. 

Male contraception research has existed for years, but now instead of recycling older hormonal models, researchers are exploring new mechanisms where the focus is now on reversible, non-hormonal, and long-acting options. This could therefore lead to a meaningful rebalance of reproductive responsibility.

Below I have compacted an overview of some of the most active approaches in the research pipeline so far: 

What it is: A daily oral pill that works by blocking a specific receptor involved in vitamin A signalling, a process necessary for sperm production.

How it works: Rather than suppressing testosterone, it targets a pathway required for sperm formation, which could reduce side effects commonly associated with hormonal manipulation.

Where it is in research: Early human Phase 1 trials have shown that it works safely in volunteers, and effectiveness studies have been planned.

Potential risks: So far, human safety data is limited but it is encouraging. Longer-term effects, reversibility, and real-world efficacy still remain under investigation.

What it is: A non-hormonal hydrogel implanted into the vas deferens (the tube carrying sperm) intended to block sperm from entering semen.

How it works: The hydrogel is in the lumen of the vas deferens, preventing sperm transport while preserving natural ejaculation and testosterone levels.

Where it is in research: Early studies have shown that this approach can effectively block sperm flow in animal models and small human studies. Its duration (measured in months to years) and the ease of reversal are still active areas of research.

Potential risks: Reversibility is still being evaluated, and there are questions about potential local tissue reaction, procedural safety, and long-term tolerability.

What it is: A single injection of a polymer gel into the vas deferens designed to block sperm movement.

How it works: Once injected, the gel creates a physical barrier that stops sperm from leaving the testicles, similar to a vasectomy but with the aim of reversibility.

Where it is in research: This strategy is being evaluated in preclinical and early clinical studies. Research organisations and community initiatives are tracking progress.

Potential risks: As with any injected material, local inflammation, blockage complications, and questions about reliably reversible sperm passage are key areas of study.

Note: While both ADAM and Vasalgel involve blocking sperm within the vas deferens using gel-based materials, they differ in design and developmental origin. Vasalgel is derived from earlier RISUG polymer research and is intended as a long-acting, potentially multi-year contraceptive that may require a flushing procedure for reversal. In contrast, ADAM is a newer hydrogel implant engineered for controlled duration, with current studies suggesting effectiveness for around one to two years with ongoing evaluation of how predictably it can be reversed or removed.

Men produce millions of sperm every day, so a contraceptive must suppress or block sperm very reliably to prevent pregnancy. There is also a regulatory nuance. Because pregnancy carries direct medical risk for women, contraceptives for women are evaluated against the health risks of pregnancy itself. For men, who do not physically experience pregnancy, regulators weigh side effects differently, often expecting extremely low risk profiles. Then combined with decades of lower investment and urgency, this helps explain why progress has been slower than many anticipated.

Forward-looking innovation in male contraception is not about replacing female methods but it is about expanding options. Reproductive health functions best when responsibility is shared, and these new technologies reflect a broader recognition that contraception is not solely a women’s burden. This therefore shows that science is evolving and conversations are widening. So, it is likely that the next decade may look very different from the last in terms of contraceptive options.

Until we have an approved male contraceptive beyond condoms and vasectomy, I think the landscape will continue to shift gradually through research publications, human trials, and just deeper discussions about shared responsibility.

Next week I want to focus in on the exciting new cervical cancer test using period blood to offer a less invasive screening process. How exciting! Until next time. 

REPROVA.

Colagross-Schouten, A. et al. (2017) “The contraceptive efficacy of intravas injection of VasalgelTM for adult male rhesus monkeys,” Basic and Clinical Andrology, 27, p. 4. Available at: https://doi.org/10.1186/s12610-017-0048-9.

Clinicaltrials.gov (no date) Clinicaltrials.gov. Available at: https://clinicaltrials.gov/study/NCT05134428 (Accessed: February 21, 2026).

Mannowetz, N., McCallum, S.W., et al. (2025) “Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529,” Communications Medicine, 5(1), p. 279. Available at: https://doi.org/10.1038/s43856-025-01004-4.

Mannowetz, N., Chung, S.S.W., et al. (2025) “Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates,” Communications Medicine, 5(1), p. 68. Available at: https://doi.org/10.1038/s43856-025-00752-7.

Matsumoto, N.M. et al. (2025) “Preclinical development of a novel injectable hydrogel for vas-occlusion,” Contraception, 145(110839), p. 110839. Available at: https://doi.org/10.1016/j.contraception.2025.110839.